Autolus Therapeutics (AUTL) Stock Price, Quote, News & History | Benzinga

Autolus Therapeutics PLC (AUTL) Stock Price, Quote, News & History

AUTLNASDAQ

Trade with Public

Trade with Public

$2.15

0.04091.94%

Last update: Aug 10, 12:27 PM

Earnings: Q2 2026 earnings tomorrow on Tue Aug 11th before the market open

Conference Call: Conference call scheduled tomorrow at 8:30 AM

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Options Stock Report

Key Statistics

Open

$2.11

Close

-

Volume / Avg.

1.35M / 1.60M

Day Range

$2.07 - $2.19

52 Wk Range

1.18 - 2.52

Market Cap

$572.45M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

75

Short Interest

8.77%

Days to Cover

10.5

Recent Autolus Therapeutics PLC News

CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday

Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 results, other stocks also recording gains.

Avi Kapoor

Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday

TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.

Avi Kapoor

Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session

US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.

Avi Kapoor

Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-273.32M

Investing Cash Flow (TTM)

314.16M

Financing Cash Flow (TTM)

-6.40M

Free Cash Flow (TTM)

-294.90M

Capital Expenditure (TTM)

-21.58M

Net Change in Cash (TTM)

34.44M

Analyst Trends and Forecast

1

Feb

2

Mar

1

Apr

1

May

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$412.08M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

6.06

PB Ratio (TTM)

5.16

Earnings Yield % (TTM)

-51.66%

Earnings Yield % (FWD)

-41.71%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.41

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$130.93M

Debt to Equity

0.73

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$2.11

Close

-

Volume / Avg.

1.35M / 1.60M

Day Range

$2.07 - $2.19

52 Wk Range

1.18 - 2.52

Market Cap

$572.45M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

75

Short Interest

8.77%

Days to Cover

10.5

About

Sector

Health Care

Industry

Biotechnology

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUT...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Autolus Therapeutics (AUTL) stock?

A

You can purchase shares of Autolus Therapeutics (NASDAQ:AUTL) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Autolus Therapeutics (AUTL) competitors?

A

Other companies in Autolus Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Autolus Therapeutics (AUTL) stock?

A

Autolus Therapeutics has a consensus price target of $9.14.

Q

What is the current price for Autolus Therapeutics (AUTL)?

A

The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.1509 last updated August 10, 2026 at 12:27 PM EDT.

Q

Does Autolus Therapeutics (AUTL) pay a dividend?

A

There are no upcoming dividends for Autolus Therapeutics.

Q

When is Autolus Therapeutics (NASDAQ:AUTL) reporting earnings?

A

Autolus Therapeutics does not have any upcoming earnings scheduled.

Q

Is Autolus Therapeutics (AUTL) going to split?

A

There is no upcoming split for Autolus Therapeutics.

Q

What sector and industry does Autolus Therapeutics (AUTL) operate in?

A

Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.